Aptuit to Invest $1 Million to Upgrade Cytotoxic Manufacturing Capabilities

Aptuit LLC announced it will be making a $1-million investment at its facility in Glasgow, Scotland facility to upgrade the site's sterile cytotoxic liquid and lyophilized drug-product manufacturing capabilities. This upgrade, which will address the industry's current need for capacity in cytotoxic GMP clinical supply, will be operational by January 2015. The installation of an autofiller with restricted access barrier technology will enable larger batch sizes for liquid and lyophilized drug products, increasing capacities from 2,000 units to more than 9,000 units. Additionally, the new equipment will achieve greater sterility assurance and operator protection.

In other news, Aptuit LLC has appointed Paul D. Overton, PhD., as executive vice president, business development and marketing, making him responsible for all of Aptuit's sales and marketing activities. He will be based in the United Kingdom and will be a member of Aptuit’s Executive Committee and report directly to Jonathan Goldman, Aptuit's chief executive officer.

Prior to joining Aptuit, Overton successfully led the global sales, marketing, and program management team at Huntingdon Life Sciences. He grew the business significantly year on year despite the challenges in the non-clinical CRO market. He was instrumental in developing late-stage discovery and translational sciences partnerships for the company. During his tenure, he realigned marketing into the sales function and rolled out a market-leading content marketing program using social media. Before his association with Huntingdon, he  held key leadership positions at Covance Laboratories, LCG Biosciences, Origin Pharmaceutical Services,and Cambridge Life Sciences.

Source: Aptuit

Leave a Reply

Your email address will not be published. Required fields are marked *